BACKGROUND:
Recommendations regarding venous thromboembolism prophylaxis in patients admitted to the hospital for IBD continue to evolve.
OBJECTIVE:
This study aimed to determine the 90-day rate and risk factors of deep venous thromboembolism and pulmonary embolism in cohorts of patients with IBD admitted to medical and surgical services.
DESIGN:
This was a retrospective review.
SETTING:
The study was conducted at a quaternary IBD referral center.
PATIENTS:
The study included adult patients (>18 y of age) with a known diagnosis of either ulcerative colitis or Crohn’s disease who had an inpatient hospital admission for IBD between January 1, 2002, and January 1, 2020.
MAIN OUTCOME MEASURES:
The primary outcome measures were 90-day rate of deep venous thromboembolism and pulmonary embolism among admitted patients.
RESULTS:
A total of 86,276 hospital admissions from 16,551 patients with IBD occurred between January 1, 2002, and January 1, 2020. A total of 35,992 patients (41.7%) were given subcutaneous heparin for venous thromboembolism prophylaxis, and 8188 patients (9.49%) were given enoxaparin for venous thromboembolism prophylaxis during the inpatient hospital admission. From the date of hospital admission, the 90-day rate of deep venous thromboembolism was 4.3% (n = 3664); of these, 1731 patients (47%) were diagnosed during the admission and 1933 patients (53%) were diagnosed after discharge. From the date of hospital admission, the 90-day rate of pulmonary embolism was 2.4% (n = 2040); of these, 960 patients (47%) were diagnosed during admission and 1080 patients (53%) were diagnosed after discharge.
LIMITATIONS:
The study was limited by its retrospective nature and unmeasured severity of the disease.
CONCLUSIONS:
Patients admitted for IBD had a 90-day deep venous thromboembolism event rate of 4.3% and pulmonary embolism event rate of 2.4%. More than half of the events occurred after discharge, and venous thromboembolism events were higher among patients with IBD admitted to a medical service than those admitted to a surgical service. See Video Abstract at http://links.lww.com/DCR/B947.
TROMBOEMBOLIA VENOSA EN PACIENTES INGRESADOS CON ENFERMEDAD INFLAMATORIA INTESTINAL: UNA EXPERIENCIA EN TODA LA EMPRESA DE 86.000 ENCUENTROS HOSPITALARIOS
ANTECEDENTES:
Recomendaciones sobre la profilaxis de tromboembolia venosa en pacientes ingresados con enfermedad inflamatoria intestinal (EII) continúa evolucionando.
OBJETIVO:
Determinar la tasa a 90 días y los factores de riesgo de tromboembolia venosa profunda y embolia pulmonar en cohortes de pacientes ingresados con EII médico y quirúrgico.
DISEÑO:
Esta fue una revisión retrospectiva.
AJUSTE:
El estudio se llevó a cabo en un centro cuaternario de derivación de EII.
PACIENTES:
Se incluyeron pacientes adultos (> 18 años) con diagnóstico conocido de colitis ulcerosa o enfermedad de Crohn que fueron hospitalizados por EII entre el 1 de Enero de 2002 y el 1 de Enero de 2020.
PRINCIPALES MEDIDAS DE RESULTADOS:
Las medidas principales fueron la tasa de trombo...